China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc. its half stake in a local joint venture tasked with the development and commercialization of Yescarta (marketed as Yikaida in China) and Tecartus in the country.
Key Takeaways
-
Gilead’s pullout from China's cell therapy market adds a fresh round of twists and turns that have complicated the commercialization push of cell therapy developers in China, regardless of their nationality.
-
By the end of July, Fosun Kite, a joint venture between Gilead/Kite and Fosun Pharma, has lost 80% of the aggregated investments of $271m made by the Sino-US partners over the past seven years
Gilead’s pullout from Fosun Kite Biotechnology Co Ltd (Fosun Kairos after the divestiture), which was founded together with Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
